{
    "title": "109_s1978",
    "content": "\"Tim Fagan's Law\" or the \"Counterfeit Drug Enforcement Act of 2005\" prohibits the sale or trade of prescription drugs that are knowingly adulterated or misbranded, or misrepresented as approved drugs. The Counterfeit Drug Enforcement Act of 2005 imposes criminal penalties for knowingly causing adulteration or misbranding of drugs subject to specific sections of the Federal Food, Drug, and Cosmetic Act. Penalties include fines, imprisonment, or both for selling, trading, purchasing, or trading drugs under violation of the Act. The Counterfeit Drug Enforcement Act of 2005 imposes penalties for misrepresenting drugs subject to specific sections of the Federal Food, Drug, and Cosmetic Act. Penalties include fines, imprisonment, or both for selling, trading, purchasing, or trading drugs under violation of the Act. Manufacturers must notify the FDA of any information suggesting drug misrepresentation. Manufacturers must report any information suggesting a violation of drug misrepresentation to the Secretary within 48 hours. SEC. 3 amends the Federal Food, Drug, and Cosmetic Act to require the use of technologies to prevent drug counterfeiting. SEC. 4 addresses statements regarding wholesale distribution of drugs. The amendment to the Federal Food, Drug, and Cosmetic Act eliminates exemptions for manufacturers and authorized distributors of record, requiring the establishment of regulations to identify the chain of custody of drugs throughout wholesale distribution. The amendment to the Federal Food, Drug, and Cosmetic Act eliminates exemptions for manufacturers and authorized distributors of record, requiring regulations to identify the chain of custody of drugs in wholesale distribution. Alternative requirements may be implemented if they can ensure the chain of custody or package identity with equal certainty and are economically and technically feasible. The amendment to the Federal Food, Drug, and Cosmetic Act mandates manufacturers to maintain a list of authorized distributors of record for drugs subject to subsection (b). The term 'authorized distributors of record' refers to distributors designated by the manufacturer and publicly listed. The amendments to the Federal Food, Drug, and Cosmetic Act require manufacturers to maintain a list of authorized distributors for certain drugs. These amendments will take effect on January 1, 2010, but the Secretary of Health and Human Services can apply them earlier for high-risk drugs if certain conditions are met. The amendments to the Federal Food, Drug, and Cosmetic Act require manufacturers to maintain a list of authorized distributors for certain drugs. Despite this requirement, wholesale distribution of a prescription drug by the manufacturer directly to a retail pharmacy for consumer distribution is exempt from these amendments. The Secretary may determine this exemption for up to 50 drugs before January 1, 2010. Additionally, alternative requirements will be established through regulations. The Secretary will establish alternative requirements for prescription drugs to prevent counterfeiting, effective by January 1, 2008 for high-risk drugs and by January 1, 2010 for all other drugs. Standardized anti-counterfeiting technologies must be used on prescription drugs by January 1, 2008. Increased funding of $60,000,000 for the FDA to conduct inspections, examinations, and investigations related to violations under the Federal Food, Drug, and Cosmetic Act. Additionally, public education efforts on counterfeit drugs will be implemented. SEC. 6. The Secretary of Health and Human Services will educate the public and healthcare professionals on identifying counterfeit drugs. $5,000,000 is authorized for this program annually from 2006 to 2010. SEC. 7. A new recall authority for drugs is added to the Federal Food, Drug, and Cosmetic Act. If a drug poses a risk of serious health consequences or death, the Secretary will issue an order to stop its distribution and notify health professionals to stop using it. An informal hearing must be provided within 10 days of the order. After issuing an order to stop distribution of a drug due to health risks, the Secretary will hold an informal hearing within 10 days. If grounds are found inadequate, the order will be vacated. If a recall is deemed necessary after the hearing, the Secretary will specify a timetable for the drug recall. The Secretary will specify a timetable for the drug recall and require periodic reports on the progress. The amended order will not recall drugs from individuals but will provide notice to those at risk. Health professionals may assist in notifying individuals at risk if they cannot be identified. The Secretary and the Attorney General will develop a procedure for the Chief Counsel in the FDA to issue subpoenas for investigations related to threats to public health under the Federal Food, Drug, and Cosmetic Act."
}